To the Security Holders of

AVITA MEDICAL, INC.

Re: 2023 Annual Meeting of StockholdersDear Stockholder,

Dear Stockholders,

You are cordially invited to attend the Annual Meetingannual meeting of Stockholders (the “Annual Meeting”)stockholders of AVITA Medical, Inc. (the “Company”). The Annual Meeting will be held virtually on June 6, 2023,5, 2024, at 3:00 p.m. Pacific Daylight Time (being June 7, 2023,6, 2024, at 8:00 a.m. Australian Eastern Standard Time). The meeting will be held in a virtual meeting format via a live audio webcast with an online voting platform at meetnow.global/MD7TYY7.MKRAKJK . You will not be able to attend the meeting atin person.

We have adopted a physical location.

All holdersvirtual meeting format as we believe it provides expanded stockholder access and participation, improves communications, and lowers our costs while reducing the environmental impact of the Company’s sharesmeeting. During the virtual meeting, you will have the opportunity to ask questions of common stock (“Common Stock”) and CHESS Depositary Interests (“CDIs”) as of 5:00 p.m. on April 13, 2023 (Pacific Daylight Time) (being 10:00 a.m. on April 14, 2023 (Australian Eastern Standard Time)) (the “Record Date”) are entitledour management with respect to receive notice of, and to vote at, the Annual Meeting. The formal Notice of the Annual Meeting follows on the next page. Details regarding the businessmatters to be conducted at the Annual Meeting are describedvoted on. AVITA Medical's accompanying proxy materials include instructions on how to participate in the accompanying Notice of Annual Meetingmeeting and Proxy Statement.

Holders of Common Stock may vote during the Annual Meeting via the online voting platform and also submit questions. Holders of CDIs will not be able to vote during the Annual Meeting via the online voting platform but will be able to submit questions virtually. Holders of CDIs can, however, direct CHESS Depositary Nominees Pty Ltd (“CDN”) to vote the Common Stock underlying their CDIs. Additionally,means by which you may vote your shares and submit questions. Please read the General Information and Voting Instructions section of Common Stock or CDIs by following the instructions on the enclosed proxy card or CDI Voting Instruction Form (as applicable). If you hold your shares of Common Stock through an account with a brokerage firm, bank, or other nominee, please follow the instructions you receive from them as to how to vote your shares of Common Stock. Further details regarding how holders of Common Stock and CDIs can vote are set out in thisaccompanying Proxy Statement. Additionally, we are promoting the use of the internet to provide proxy materials to stockholders as this is a cost-effective and environmentally responsible method for disseminating materials for our annual meeting.

Your vote is extremely important. The Company hopes thatencourages all eligible holders of its Common Stockshares of common stock and CDIsCHESS Depositary Interests to participate in the Annual Meeting virtually. Whether or not you plan to attend the virtual Annual Meeting, you are urged toannual meeting, please vote your shares promptly vote or submit your proxy card or CDI Voting Instruction Form as soon as possible so that your shares of Common Stock (or shares of Common Stock underlying your CDIs) will be represented and voted at the Annual Meetingannual meeting in accordance with your instructions.

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

TO BE HELD ON JUNE 6, 2023,5, 2024, AT 3:00 PM PACIFIC DAYLIGHT TIME (BEING

JUNE 7, 20236, 2024 AT 8:00 AM AUSTRALIAN EASTERN STANDARD TIME)

To the Stockholders of AVITA Medical, Inc.

AVITA MEDICAL, INC.

NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders (the "Annual Meeting") of AVITA Medical, Inc. (the “Company”("we", "us", or the "Company"), a Delaware corporation, will be held on June 6, 2023,5, 2024, at 3:00 p.m. Pacific Daylight Time (being June 7, 2023,6, 2024, at 8:00 a.m. Australian Eastern Standard Time), by way of. The Annual Meeting will be held in a virtual meeting conductedformat via a live audio webcast with an online voting platform at meetnow.global/MD7TYY7MKRAKJK for the following purposes:

The Board of Directors has fixed 5:00 p.m. (PacificPacific Daylight Time)Time on April 13, 202311, 2024 (being 10:00 a.m. AESTAustralia Eastern Standard Time on April 14, 2023)12, 2024) as the record date ("Record Date") for the Annual Meeting and only record holders of sharesMeeting. Holders of Common Stock at that time will beand holders of the Company's CHESS Depositary Interests ("CDIs") as of the Record Date are entitled to receive notice of, and to electronicallysubmit a vote at, the

for, this Annual Meeting or any adjournment or adjournments thereof. Holders of CDIs ofPlease read the Company at that time will be entitled to receive notice of,General Information and to virtually attend (but not vote at), the Annual Meeting or any adjournment or adjournments thereof. Voting Instructions section in this Proxy Statement for further important information.

This Proxy Statement and the accompanying proxy and CDI Voting InstructionProxy Form are being mailedavailable online at www.edocumentview.com/RCEL to stockholders on or about April 18, 2023.23, 2024.

Valencia, CA XXXX, 2023

April 17, 2024

AVITA MEDICAL, INC.

28159 Avenue Stanford, Suite 220

Valencia, CA 91355

PROXY STATEMENT

for

ANNUAL MEETING OF STOCKHOLDERS

to be held on June 6, 2023,5, 2024, at 3:00 p.m. (PacificPacific Daylight Time)Time

(being June 7 2023,6, 2024, at 8:00 a.m. (AustralianAustralian Eastern Standard Time (“AEST”))Time)

SOLICITATION OF PROXY

The accompanying proxy is solicited on behalf of the board of directors (the “Board of Directors” or “Board”) of AVITA Medical, Inc., a Delaware corporation (“AVITA” or the “Company”),Company, for use at the annual meeting of stockholders of the Company (the “Annual Meeting”) to be held on June 6, 2023,5, 2024, at 3:00 p.m. Pacific Daylight Time (being June 7, 2023,6, 2024, at 8:00 a.m. Australian Eastern Standard Time)Time ("AEST")) by way of a virtual meeting conducted via live webcast with an online voting platform at meetnow.global/MD7TYY7.MKRAKJK. This Proxy Statement contains information about the matters to be considered at the meeting or any adjournments or postponements of the meeting. In addition to mail, proxies may be solicited in person or by telephone, facsimile and email by the Company’s directors, officers and regular employees, without additional compensation. The Company will bear the cost of solicitation of proxies. In addition to solicitation by mail, the Company's directors, officers, and regular employees may solicit proxies in person, by telephone, or via other means of communication without additional compensation. Brokerage houses, banks and other custodians, nominees, and fiduciaries will be reimbursed for out-of-pocket and reasonable expenses incurred in forwarding proxies and proxy statements.

The Board of Directors has set 5:00 p.m. Pacific Daylight Time on April 13, 202311, 2024 (being 10:00 a.m. AEST on April 14, 2023)12, 2024) as the record date (the “Record Date”) to determine those holders of record of shares of common stock ("Common StockStock") who are entitled to notice of, and to electronically vote at, the Annual Meeting and those holders of CHESS Depositary Interests (“CDIs”) (representing the underlying shares of Common Stock) who are entitled to notice of, and to virtually attend (but not vote at), the Annual Meeting. Each share of Common Stock (including the underlying shares of Common Stock represented by CDIs, with five CDIs representing one share of Common Stock) entitles its owner to one vote. On the Record Date, there were xx,xxx,xxxXX,XXX,XXX shares of Common Stock outstanding (including the shares of Common Stock underlying CDIs).

On or about April 18, 2023, this Proxy Statement, the23, 2024, we will begin disseminating notices of proxy card (the “Proxy Card” or “Proxy”) and the CDI Voting Instruction Form (as applicable) are being mailedmaterial availability to our stockholders and CDI holders of record as of the Record Date.Date, directing stockholders to a website where they can access our proxy materials, including this proxy statement and our 2023 Annual Report, and view instructions on how to vote online.

IMPORTANT: To ensure that your shares of Common Stock are represented at the Annual Meeting, please vote your shares of Common Stock (or, for CDI holders, direct CHESS Depositary Nominees Pty Ltd (“CDN”) to vote your CDIs) via marking, signing, dating, and returning the enclosed Proxy Card or CDI Voting Instruction Form (as applicable) to the address specified. If you attendHolders of Common Stock, as of the Record Date, may vote during the virtual Annual Meeting you may vote via the online platform at meetnow.global/MD7TYY7 if you qualify to do so,MKRAKJK, even if you have previously voted your shares of Common Stock, except thatStock. CDI holders may only instruct CDN to vote on their behalf by completing and signing the CDI Voting Instruction Form and mayare not eligible to electronically vote during the virtual Annual Meeting.

ABOUT THE MEETING

How will I receive these proxy materials?

We are furnishing proxy materials to our stockholders via the internet instead of mailing printed copies, unless otherwise requested by the stockholder. This process allows us to expedite communication to our stockholders, reduces the environmental footprint of our Annual Meeting as well as the costs associated with printing and mailing these materials to all stockholders.

Accordingly, on or about April 23, 2024, we will begin mailing notices of proxy material availability to our stockholders of record at the close of business on the Record Date. All record and beneficial stockholders will have the ability to access the proxy materials on the website referred to in the notices free of charge or request to receive a printed set of the proxy materials for the Annual Meeting. Instructions on how to access the proxy materials over the internet or to request a printed copy may be found in the notices.

Brokers, banks and other nominees will be sending a similar notification to all beneficial owners of stock who hold their shares through such broker, bank or nominee.

What is being considered at the meeting?

You will be voting on the following:

What does it mean to be a holder of CDIs?

CDIs are issued by the Company through CDN and traded on the Australian Securities Exchange (the “ASX”). If you own the Company’s CDIs, then you are the beneficial owner of one share of Common Stock for every five CDIs that you own. CDN or its custodian is considered the shareholder of record for the purposes of voting at the Company’s Annual Meeting. As the beneficial owner, you have the right to direct CDN or its custodian as to how to vote the shares in your account. As a beneficial owner, you are invited to attend the Annual Meeting. However, because you are not a stockholder of record, if you personally want to vote the shares of Common Stock underlying your CDIs at the Annual Meeting, you must inform CDN via your CDI Voting Instruction Form that you wish to nominate yourself (or another person, including the Chair of the Annual Meeting) to be appointed as CDN’s proxy for the purposes of virtually attending and voting at the Annual Meeting.

Under the rules governing CDIs, CDN is not permitted to vote on your behalf on any matter to be considered at the Annual Meeting unless you specifically instruct CDN how to vote. The Company encourages you to communicate your voting decisions to CDN in advance of the Annual Meeting to ensure that your vote will be counted by completing the enclosed CDI Voting Instruction Form and returning it to the address specified on that form.

How many votesshares must be present or represented to hold the meeting?

Your shares are counted as present at the meeting if you attend the meeting virtually and vote via the online platform at meetnow.global/MD7TYY7MKRAKJK or if you properly return a Proxy (in the case of holders of Common Stock) or CDI Voting Instruction Form (in the case of holders of CDIs). To conduct the meeting, the holders of not less than a majority in voting power of the outstanding shares of stock entitled to vote must be present at the meeting in person or by proxy. This is referred to as a quorum. On the Record Date, there were xx,xxx,xxxXX,XXX,XXX outstanding shares of Common Stock (including Common Stock underlying CDIs) entitled to vote.

How do I vote if I hold shares of Common Stock?

Registered holders of Common Stock can vote in three ways:

collection and processing of voting instructions from the Company’s CDI holders. holders; or

If a CDI holder does not include voting instructions in the CDI Voting Instruction Form in respect of a proposal no vote will be cast on that proposal for that CDI holder.

What does it mean if I receive more than one Proxy Card or CDI Voting Instruction Form?

If you receive more than one printed set of proxy materials, it means that you hold Common Stock or CDIs registered in more than one account. To ensure that all of your Common Stock or CDIs are voted, please submit proxies or CDI Voting Instruction Forms for all of your shares of Common Stock or CDIs (as applicable).

If possible, the Company recommends that you contact your broker and/or the Company’s transfer agent to consolidate as many accounts as possible under the same name and address. The Company’s transfer agent in the United States is Computershare Limited. Computershare Limited’s telephone number is 800-736-3001. The Company’s transfer agent in Australia is Computershare Australia. Computershare Australia’s telephone number is +61 39415 4000 (for overseas callers) or 1300 850 505 (for calls within Australia).

What vote is required to approve each item?

Directors are elected by a plurality of votes cast and the affirmative vote of the holders of a majority in voting power of the shares of stockCommon Stock of the Company which are present in person or by proxy and entitled to vote thereon is required for (i) the ratification of the appointment of the Company’s independent public accountants; (ii) the approval of the grant of restricted stock units and options to each non-executive director; (iii) the approval of the grant options to the Company’s President and CEO; (iv) the approval for the Plan Amendment; (v) the approval of the Employee Stock Purchase Plan; and (vi)(iv) the approval of the compensation paid to the Company’s named executive officers on a non-binding, advisory basis.

Which ballot measures are considered “routine” or “non-routine”?

The election of directors (“Proposal No. 1”), the grants of restricted stock units and option awards to our directors (“Proposals Nos. 3 – 8”), the grant of options to our CEO (“Proposal No. 9”), and the approval, on a non-binding advisory basis, of the compensation paid to our named executive officers (“Proposal No. 10”) are considered to be non-routine matters under applicable rules. A broker or other nominee cannot vote without instructions on non-routine matters, and therefore there may be broker non-votes on Proposal 1, Proposals Nos. 3-8, Proposal 9 or Proposal 10.

Where can I find the voting results of the Annual Meeting?

The preliminary voting results will be announced at the Annual Meeting. In accordance with the requirements of ASX Listing Rule 3.13.2, the Company will disclose to ASX the voting results of the Annual Meeting immediately after the meeting. The Company will also report the results on a Current Report on Form 8-K filed with the U.S. Securities and Exchange CommissionSEC within four business days following the Annual Meeting.

Who pays for solicitation of proxies?

The Company is paying the cost of soliciting proxies and may request a proxy solicitor, brokerage firms and other custodians, nominees, and fiduciaries to secure the voting instructions of holders of Common Stock and CDIs, in which case the Company will reimburse such persons for their reasonable out-of-pocket and reasonable expenses for sending proxy materials to holders and obtaining their votes. In addition to soliciting the proxies by mail, certain of the Company’s directors, officers and regular employees, without compensation, may solicit proxies personally orin person, by telephone, facsimile and email.or other means of communication. In connection with the foregoing, the Company has retained Okapi Partners LLC to solicit proxies on its behalf for the Annual Meeting. The Company has agreed to pay to Okapi Partners, LLC a fee of approximately $25,000. In Australia, the Company has engaged Georgeson Shareholder Communications Australia Pty Ltd. to solicit proxies from holders of CDIs. The Company has agreed to pay Georgeson Shareholder Communications Australia Pty Ltd. a fee of approximately $48,000.

How can I submit a proposal for the 2024 annual meeting of stockholders?

Proposal No. 1

ELECTION OF DIRECTORS

The Company’s Board of Directors has one class of directors, with each director elected annually in accordance with the Company’s Bylaws for a term of one year or until his or her successor is duly elected and qualified, subject to such director’s earlier death, resignation, disqualification or removal. Unless specified to be voted otherwise, the persons named in the accompanying Proxy will vote for the election of the following persons as directors, all of whom are presently members of the Board of Directors, to hold office for the terms set forth below or until their respective successors have been elected and qualified. Each of the nominees has consented to serve as a director if elected.

The Board of Directors recommends that you vote for the nominees identified below.

Business Experience

Lou Panaccio has served as Non-Executive Chairman of the Board of Directors since July 2014. Mr. Panaccio is a successful healthcare businessman with extensive experience leading companies from concept to commercialization. Mr. Panaccio possesses more than 35 years of executive leadership experience in healthcare services and life sciences, including more than 25 years of board-level experience. Mr. Panaccio is currently a Non-Executive Director of ASX50 company and one of the world’s largest medical diagnostics companies, Sonic Healthcare Limited, where he has served since 2005. In addition, Mr. Panaccio is a Non-Executive Director of Unison Housing Limited, was a Non-Executive Chairman of Genera Biosystems Limited until June 2019, is a Non-Executive Chairman of Adherium Limited and a Non-Executive Director of Rhythm Biosciences Limited, both of which are publicly listed (ASX) development-stage medical diagnostics/devices companies. We believe Mr. Panaccio is qualified to serve on our Board of Directors based on his extensive experience in the healthcare services and life sciences sectors and his experience in serving on boards.

James Corbett was appointed as President and CEO of the Company effective as of September 28, 2022. Mr. Corbett served as a Non-Executive Director from July 2021 to September 28, 2022. He has approximately 40 years of leadership experience in the medical device field, most recently, as CEO of CathWorks Ltd., a software-based medical technology company. Mr. Corbett has extensive global commercial and operating experience, serving as an expatriate General Manager of Baxter Japan and later as General Manager and President of Scimed Life Systems Inc. and Boston Scientific International respectively. During his career he has served as CEO of three publicly listed companies; Microtherapeutics Inc (MTIX), ev3 Inc (evvv), and, Alphatec Spine (ATEC). Mr. Corbett has also led two privately funded companies as CEO: Home Diagnostics Inc. and Vertos Medical. Mr. Corbett has extensive capital market and governance experience from both public and private environments. Mr. Corbett holds a Bachelor of Science in Business Administration from the University of Kansas. Mr. Corbett is a board member of two privately held medical device companies. We believe Mr. Corbett is qualified to serve on our board of directors based on his global commercial and operating expertise in supporting companies with their medical and scientific strategies.

Jeremy Curnock Cook has served as a Non-Executive Director since October 2012. He is a veteran in the life sciences/healthcare industry and has been actively supporting the commercialization of healthcare innovations and helping entrepreneurs build their international businesses over the past 45 years. Founder and Managing Director of BioScience Managers, Mr. Curnock Cook brings his decades of international experience to our Board of Directors. Over his career, Mr. Curnock Cook has successfully managed in excess of US $1 billion in equity investments. He launched the first dedicated biotechnology fund for the Australian market and is a former head of the life science private equity team at Rothschild Asset Management, an early pioneer and significant investor in the sector. In his early career he founded the International Biochemicals Group which he successfully sold to Royal Dutch Shell. Mr. Curnock Cook co-created a European-focused seed fund with Johnson & Johnson and built the International Biotechnology Trust. Mr.

Curnock Cook has served on more than 40 boards of directors in the life science sector in the UK, Europe, USA, Canada, Japan and Australia. In addition to serving on our Board of Directors, Mr. Curnock Cook currently serves on the following boards: International BioScience Managers Ltd appointed March 2000, Bioscience Managers Pty Ltd appointed January 2003, REX Bionics Pty Ltd appointed February 2012, Sea Dragon appointed October 2012, Adherium Ltd appointed April 2015, Bioscience Managers UK Ltd appointed August 2017, Marine Department Ltd, appointed January 2019, JLCC Ltd appointed December 2019, CRiLCriL appointed November 2020 and Humanetix Ltd appointed September 2021. We believe Mr. Curnock Cook is qualified to serve on our Board of Directors based on his extensive experience in the life sciences sector.

Professor Suzanne Crowe AO has served as a Non-Executive Director since January 2016. Australian-based, she is a physician-scientist and ASX/Nasdaq-listed company director with expertise in supporting companies with their medical and scientific strategies. A Fellow of the Australian Institute of Company Directors, and Emeritus Professor, Monash University Melbourne, she is currently a Non-Executive Director of Sonic Healthcare Ltd, a large global medical diagnostics company. Past board positions include St Vincent’s Health Australia Ltd (2012-2021), the country’sAustralia’s largest not-for-profit health and aged care provider. After 35 years at both, she has recently retired from the Burnet Institute, having served as Associate Director Clinical Research, and The Alfred Hospital Melbourne, where she held the appointment of Senior Specialist Physician in Infectious Diseases. She was appointed as Officer of the Order of Australia in June 2020 in recognition of her distinguished services to health, clinical governance, biomedical research, and education. We believe Professor Crowe is qualified to serve on our Board of Directors based on her technical experience and extensive expertise in supporting companies with their medical and scientific strategies.

Jan Stern Reed has served as a Non-Executive Director since July 2021. She has more than 35 years of legal, management and business leadership experience primarily within the healthcare industry, and brings significant expertise in corporate governance, compliance, and risk management. Ms. Reed served as Senior Vice President, General Counsel and Corporate Secretary at Walgreens Boots Alliance, Inc., a global pharmacy-led, health and wellbeing company. Prior to Walgreens, Ms. Reed was Executive Vice President, Human Resources, General Counsel and Corporate Secretary of Solo Cup Company, where she was responsible for the legal, human resources, internal audit, corporate communications, and compliance functions. Prior to Solo Cup Company, she was Associate General Counsel, Corporate Secretary and Chief Corporate Governance Officer at Baxter International, Inc. Ms. Reed holds a Bachelor of Arts degree from the University of Michigan and a Juris Doctor from the Northwestern University Pritzker School of Law. Ms. Reed currently serves as a board member of Stepan Co. (NYSE: SCL), a major manufacturer of specialty and intermediate chemicals used in a broad range of industries, and AngioDynamics, Inc. (NASDAQ: ANGO), an industry-leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients. We believe Ms. Reed is qualified to serve on our Board of Directors based on her extensive experience in legal, human resources, corporate governance, general management and business leadership, primarily within the healthcare industry.

Robert McNamara is a director nominee and appointed to servehas served as a Non-Executive Director effective April 1, 2023. He is an accomplished senior executive with over 25 years of leadership experience in public and privately held companies in the medical device and technology industries. His extensive experience in operations and

financial management spans across early stage, high growth, and mature companies. He is currently a member of the Board of Directors and Chair of the Audit Committee for Axonics, Modulation TechnologiesInc. and Teknova. Additionally, Mr. McNamara is a member of the Board of Directors and Chair of the Compensation Committee for Xtant Medical Holdings. Prior to these appointments, Mr. McNamara served as Executive Vice President, Chief Financial Officer of LDR Holding/Spine. Prior to this role, he served as the Chief Financial Officer of three publicly traded medical device companies including Accuray, Somnus Medical Technologies, and Target Therapeutics. Mr. McNamara holds a Bachelor of Science in Accounting from the University of San Francisco and an MBA.MBA from The Wharton School, University of Pennsylvania. We believe Mr. McNamara is qualified to serve on our Board of Directors because of his experience with financial management and other requirements of U.S. public and private companies, and considerable expertise in the medical device and technology industries.

Cary Vance is a director nominee and appointed to servehas served as a Non-Executive Director effective April 1, 2023. He has over 25 years of extensive leadership experience with commercial and operational expertise in the healthcare industry. He is currently the President and Chief Executive Officer of Titan Medical, a position he has held since July 2022. Prior to this appointment, he served as an independent director for Titan Medical’s Board of Directors. Previously, Mr. Vance served as President and CEO of XCath,Xcath, a privately held neurovascular robotics company, having also served in similar roles at OptiScan Biomedical and Myoscience. Prior to these roles, he served as President and CEO of Hansen Medical, a publicly held robotics company from 2014 to 2016. Additional executive leadership experience includes roles include at Teleflex, Covidien, and GE Healthcare. Mr. Vance is Lean/Six Sigma Black Belt Certified, and holds both a Bachelor of Arts degree in Economics and an MBA from Marquette University. We believe Mr. Vance is qualified to serve on our Board of Directors based on his leadership experience and extensive expertise in commercial and operations in the healthcare industry.

Current Committee Table (as of March 28, 2023)February 22, 2024)

The current committees of the Board and their respective members are as follows:

Each of these committees operates under a written charter and reports regularly to the Board.Board of Directors. A copy of each of these committee charters is available in the “Investors” section of the Company’s website under the heading “Corporate Governance” at ir.avitamedical.com, and copies may also be obtained by request through the “Contact” heading at the same website address. Our Internet website and the information contained therein or connected thereto are not intended to be incorporated into this Proxy Statement.

Audit Committee

Nasdaq Marketplace Rules require us to establish an audit committee comprised of at least three members, each of whom is financially literate and satisfies the respective “independence”independence requirements of the SEC and Nasdaq and one of whom has accounting or related financial management expertise at senior levels within a company. In addition, the 4th ASX Listing Rules and the 4th Edition of the ASX’s Corporate Governance Principles and Recommendations recommend that the Company hasrequire us to have an Audit Committee comprised of at least three members, all of whom are non-executive directors Directors and a majority of whom are “independent” directors,independent Directors, and which is chaired by an independent directorDirector who is not the chair of the board.Board.

The Company has

We have a separately designatedseparately-designated standing Audit Committee established in accordance with Section 3(a)(58)(A) of the Exchange Act. The Company’sOur Audit Committee assists theour Board of Directors in overseeing the

accounting and financial reporting processes of the Companyour company and audits of itsour financial statements, including the integrity of the Company’sour financial statements, compliance with legal and regulatory requirements, the Company’sour registered public accounting firm’s qualifications and independence, and such other duties as may be directed by theour Board of Directors. The Audit Committee is also required to assess risk management in conjunction with the Board.Board of Directors.

The Company’s

Our Audit Committee currently consists of threefour Board members, each of whom satisfies the “independence”independence requirements of the SEC, Nasdaq Marketplace Rules, the ASX Listing Rules and the 4th4th Edition of the ASX’s Corporate Governance Principles and Recommendations. The Company’sOur Audit Committee is currently composed of Jeremy Curnock Cook,Robert McNamara, Lou Panaccio, and Jan Stern Reed.Reed and Cary Vance. Each qualifies as an “independent director”independent director within the meaning of Nasdaq Marketplace Rules and the 4th 4th Edition of the ASX’s Corporate Governance Principles and Recommendations. Mr. CorbettCurnock-Cook was theinterim Chairman of the Audit Committee from February 23,September 2022 through September 28, 2022.April 2023. Mr. Corbett stepped down from his role on the Audit Committee following his appointment to President and CEO of the Company on September 28, 2022. Prior to his appointment to President and CEO, Mr. Corbett was an independent director. Mr. Curnock CookRobert McNamara is the current Interim Audit Committee Chair and was appointed to that role as of September 28, 2022,May 2023, following Mr. Corbett’s transitionhis appointment to President and CEOthe Board of the Company. The Company’sDirectors. Our Board of Directors has determined that Mr. Curnock CookRobert McNamara is an “auditaudit committee financial expert,” as defined in item 407(d)(5)(ii) of Regulations S-K. The Audit Committee meets at least four times per year.

The Audit Committee held a total of sixfive meetings during the yearannual period ended December 31, 2022. The2023. All members of the Audit Committee attended at least 75% of the meetings attended by each Director, andheld during the number of meetings thattime in which they were eligible to attend, isa member of the Audit Committee. In addition, James Corbett was not a member of the Audit Committee, but was in attendance at all Audit Committee meetings in 2023 as follows:CEO.

Compensation Committee

The Company’s

Our Board of Directors has established a Compensation Committee, which is comprised of independent directors,Directors, within the meaning of NASDAQNasdaq Marketplace Rules and also the 4th4th Edition of the ASX’s Corporate Governance Principles and Recommendations. The Compensation Committee ismust be comprised solely of non-executive directors in accordance with the ASX Listing Rules and ismust also be chaired by an independent directorDirector in accordance with the 4th4th Edition of the ASX’s Corporate Governance Principles and Recommendations. The Compensation Committee is responsible for reviewing the salary, incentives, and other benefits of the Company’s our

directors, senior executive officers and employees, and for making recommendations on such matters for approval by theour Board of Directors. The Compensation Committee is also responsible for overseeing and advising the Company’sour Board of Directors with regard to the adoption of policies that govern our compensation programs. Professor Suzanne Crowe, Jeremy Curnock Cook, Jan Stern Reed, Cary Vance and Lou Panaccio are the current members of the Compensation Committee, and each qualifies as an “independent director”independent Director within the meaning of NASDAQNasdaq Marketplace Rules and the 4th4th Edition of the ASX’s Corporate Governance Principles and Recommendations. Cary Vance is the Chair of the Compensation Committee.

The Compensation Committee held a total of five meetings during the annual period ended December 31, 2023. All members of the Compensation Committee attended at least 75% of the meetings held during the time in which they were a member of the Compensation Committee. James Corbett was not a member of the Compensation Committee, but was in attendance at all Compensation Committee meetings in 2023 as CEO.

Ms. Jan Stern Reed stepped down from the role as Compensation Committee Chair and was appointed by the Board of Directors to serve as a Compensation Committee member, with effect from May 10, 2023. Mr. Vance was appointed by the Board of Directors to serve as a member of the Compensation Committee, with effect from May 10, 2023. Mr. Vance was then appointed to Compensation Committee Chair beginning with the August 9, 2023 meeting.

Nominating & Corporate Governance Committee

Our Board of Directors has established a Nominating and Corporate Governance Committee. Under the 4th Edition of the ASX’s Corporate Governance Principles and Recommendations, our Nominating and Corporate Governance Committee should have at least three members, a majority of whom are independent, and should also be chaired by an independent director. Professor Suzanne Crowe, Robert McNamara, Jan Stern Reed and Jeremy Curnock Cook are the current members of the Nominating and Corporate Governance Committee and each qualifies as an independent director within the meaning of Nasdaq Marketplace Rules and the 4th Edition of the ASX’s Corporate Governance Principles and Recommendations. Jan Stern Reed is the chairChair of the Compensation Committee (being an independent director who is not the chairNominating and Corporate Governance Committee. Lou Panaccio stepped down as a member of the board).

The CompensationNominating and Corporate Governance Committee held a total of 10four meetings during the yearannual period ended December 31, 2022. The meetings attended by each Director, and the number of meetings that they were each eligible to attend is as follows:

Nominating & Corporate Governance Committee

The Company’s Board of Directors has established a Nominating & Corporate Governance Committee (the “Nominating Committee”). The 4th Editionattended at least 75% of the ASX’s Corporate Governance Principles and Recommendations recommends thatmeetings held during the time in which they were a Nominating Committee should have at least three members, a majority of whom are independent directors and should also be chaired by an independent director. Professor Suzanne Crowe, Lou Panaccio, Jan Stern Reed and Jeremy Curnock Cook are the current membersmember of the Nominating Committee, and each qualifies as an “independent director” within the meaning of NASDAQ Marketplace Rules and the 4th Edition of the ASX’s& Corporate Governance Principles and Recommendations. Jan Stern Reed is the chairCommittee. James Corbett was not a member of the Nominating and Corporate Governance Committee, (being an independent director). but was in attendance at all Nominating and Corporate Governance Committee meetings in 2023 as CEO.

The Nominating and Corporate Governance Committee is responsible for identifying individuals qualified to become members of theour Board of Directors, recommending nominees for election at stockholderthe stockholders meetings or to fill vacancies that arise on the Company’sin our Board of Directors, and recommending qualified and experienced directors to serve on the committees of theour Board of Directors. In addition, the Nominating and Corporate Governance Committee is responsible for leadingensuring that the Board and each of Directors through the completion of a self-evaluation of the Board, its committees conducts an annual self-evaluation.

Additionally, the Nominating and individual directors.Corporate Governance Committee oversees, reviews, and receives updates on the Company’s significant legal and regulatory compliance matters, provided that matters with financial implications will be referred to and reviewed by the Audit Committee. Matters within the Committee’s oversight responsibilities may include, without limitation, compliance with laws, fair dealing, employee health and safety, data privacy, employment, anti-bribery, work environment, interactions with health care professionals, and product quality compliance.

The Nominating and Corporate Governance Committee held a total of four meetings duringalso oversees, reviews, and receives updates regarding the year ended December 31, 2022. The meetings attendedCompany’s ethics and compliance issue reporting mechanisms and significant investigations. This includes reviewing reports on (i) the process for how ethics and compliance issues are identified and reported to the compliance department; (ii) all significant investigations directed by each Director,the compliance department pursuant to the Company’s compliance hotline and other reporting mechanisms maintained by the number of meetings that they were eligible to attend, isCompany; and (iii) reinforcing the need for independence, objectivity, professionalism and confidentiality as follows:guiding principles in the investigative process.

Process for Nominating Potential Director Candidates

The Nominating and Corporate Governance Committee is responsible for identifying and evaluating potential director candidates and recommending qualified candidates for election by the stockholders consistent with criteria approved by the Board. Nominees for director are selected by the Nominating and Corporate Governance Committee on the basis of their (i) economic,

academic, financial, and other expertise, skills, knowledge, and achievements useful to the oversight of the Company’s business; (ii) integrity, demonstrated sound business judgment, and high moral and ethical character; (iii) diversity of viewpoints, backgrounds, experiences, and other demographics; (iv) business or other relevant professional experience; (v) capacity and desire to represent the balanced, best interests of the Company and its stockholders as a whole and not primarily a special interest group or constituency; (vi) ability and willingness to devote time to the affairs and success of the Company and in fulfilling the responsibilities of a director; and (vii) the extent to which the interplay of the candidate’s expertise, skills, knowledge, and experience with that of other Board members will build a Board that is effective, collegial, and responsive to the needs of the Company.

The Nominating and Corporate Governance Committee does not have a formal diversity policy with respect to the Board, but itidentifies candidates of diverse backgrounds and considers all candidates equally. The Nominating and Corporate Governance Committee reviews the background and qualifications of each nominee to determine such nominee’s experience, competence, and character, and assesses such nominee’s potential contribution to the Board of Directors, taking into account the then-existingthen existing composition of the Board of Directors and such other factors as the Nominating and Corporate Governance Committee deems appropriate. The Board should collectively possess skills, industry, and other knowledge and expertise, and business and other experience useful for the effective oversight of the Company’s business. The Nominating and Corporate Governance Committee believes that the business experience of its directors has been, and continues to be, critical to the Company’s development and plan of operation.

The Nominating and Corporate Governance Committee values the input of stockholders in identifying director candidates. Accordingly, although the Nominating and Corporate Governance Committee does not have a specific policy with regard to the consideration of candidates recommended by stockholders, the Nominating and Corporate Governance Committee considers recommendations for Board candidates submitted by stockholders using substantially the same criteria as it applies to recommendations from the Nominating and Corporate Governance Committee, directors and members of management. Any such nominations should be submitted to the Nominating and Corporate Governance Committee in line with the instructions provided later in this Proxy Statement under the caption “How can I submit a proposalRequirements for Stockholder Proposals to be Brought Before the 2024 annual meeting2025 Annual Meeting of stockholders?” aboveStockholders and in compliance with other specific procedural requirements set forth in the Bylaws.

Board Meetings

During

The Board of Directors held a total of seven meetings during the yearannual period ended December 31, 2022,2023. Robert McNamara and Cary Vance were elected to the Board of Directors met a totalon April 1, 2023. All members of twelve times. Thethe Board of Directors attended at least 75% of the meetings attended by each Director, andheld during the number of meetings thattime in which they were each eligible to attend is as follows:a member of the Board of Directors.

Additionally, during the calendar year throughending December 31, 2023,2024, the Board of Directors areis currently scheduled to meet five times.

Code of Business Conduct and Ethics

The Company has adopted a written code of business conduct and ethics that applies to all Company directors, officers and employees. A copy of the code is posted under the heading “Corporate Governance” on the Investor Relations section of the Company’s website, which is located at https://avitamedical.com/. If the Company makes any substantive amendments to, or grants any waivers from, the code of business conduct and ethics for any officer or director, the Company will disclose the nature of such amendment or waiver on its website or in a current report on Form 8-K.

Board Leadership Structure

The current non-executive Chairman of the Board of Directors is Lou Panaccio, who is an independent director under NASDAQNasdaq listing standards and for the purposes of the ASX Listing Rules and the 4th Edition of the ASX Corporate Governance Council’s Corporate Governance Principles and Recommendations. The roles of Chairman of the Board and Chief Executive Officer are separate. The Board of Directors believes that the separation of the offices of the Chairman of the Board and Chief Executive Officer allows the Company’s Chief Executive Officer to focus primarily on the Company’s business strategy, operations, and corporate vision. The Board of Directors consists of a majority of independent non-executive directors, and each of the committees of the Board of Directors is comprised solely of independent non-executive directors. The Company does not have a policy mandating an independent lead director. The independent directors meet at least annually in executive session without the presence of the non-independent director.

Risk Oversight

While management is responsible for assessing and managing risks to the Company on a day-to-day basis, the Company’s Board of Directors oversees management’s efforts to assess and manage risk. The Board (in conjunction particularly with the Audit Committee) monitors and receives advice on areas of operational and financial risk and considers strategies for appropriate risk management arrangements. Specific areas of risk which are regularly considered at Board meetings include foreign currency, performance of activities, human resources, acceptance by regulatory authorities of the Company’s products, markets, manufacturing, the environment, statutory compliance, and continuous disclosure obligations. Additional areas of focus for the Board of Directors include, but are not limited to:

More broadly, risks are considered in virtually every business decision and process and as part of the Company’s overall business strategy. While the Board of Directors has the ultimate oversight responsibility for the Company’s risk management policies and processes, the committees of the Board of Directors also have responsibility for risk oversight. As noted above, the Company’s Audit Committee assists the Board of Directors to meet its

oversight responsibilities in respect of various areas of risk for the Company including risks associated with its financial statements and financial reporting, internal control structure, risk management procedures and the internal (as applicable) and external audit function as well as mergers and acquisitions, credit and liquidity, and, in conjunction with the Nominating and Corporate Governance Committee, business conduct compliance. The Compensation Committee considers the risks associated with the Company’s compensation policies and practices with respect to both executive compensation and employee compensation. The Nominating and Corporate Governance Committee oversees risks associated with the Company’s overall governance practices and the leadership structure of the Board of Directors.

The Company’s Board of Directors stays informed of each committee’s risk oversight and other activities via regular reports of the committee chairs to the full Board of Directors. The Board of Directors’ role in risk oversight is consistent with the Company’s leadership structure, with the Chief Executive Officer and other members of senior management having responsibility for assessing and managing the Company’s risk exposure, and the Board of Directors and committees providing oversight in connection with those efforts.

Cybersecurity Risk Management and Strategy

The Company has implemented an Information Security Management System (“ISMS”). The Company’s ISMS is a continuous process designed to analyze the potential risks, vulnerabilities, the likeliness of occurrence and the related consequences of cybersecurity threats. The process is based on establishing the context, assessing the risks, and treating the risks. The key concept of the ISMS is to consistently maintain and improve confidentiality, integrity, and availability of information assets that should be protected by the organization on behalf of itself and its clients, and third parties. Once a risk, threat or vulnerability is identified, the Company establishes a risk treatment plan to take corrective action to prevent risks that can be avoided and minimize the ones that cannot. The Company engages an independent third-party cybersecurity services and consulting firm to continuously review our information security. The Company also conducts internal phishing campaigns and performs an independent penetration test on an annual basis. In addition, we conduct regular security awareness training and testing of our employees. The Company has not had any material cybersecurity incidents.

The Company’s ISMS is established in accordance with the requirements of International Organization for Standardization 27001 and 27002 (“ISO 27001” and “ISO 27002”). The ISO 27001, Information security management systems, provides a framework and guidelines for establishing, implementing and managing an ISMS and ISO 27002, Information security controls, provides a reference set of generic information security controls including implementation guidance.

Disclosure of Management’s Responsibility

The Company’s Chief Financial Officer ("CFO") is primarily responsible for overseeing the Cybersecurity Risk Management Program and leading the Company’s efforts to mitigate technology risks in partnership with various business leaders in the organization. For qualifications of the CFO refer to Item 10 of the 2023 Form 10-K, filed with the SEC on February 22, 2024 (and ASX on February 23, 2024). The Company has protocols, policies and tools in place to mitigate cybersecurity risk. They also provide the administrative, technical, and physical safeguards to ensure the security, confidentiality, integrity and availability of confidential information and personal information from unauthorized access, use, disclosure, alteration, destruction or theft. In addition, the Company engages an independent third party annually to assess our IT general controls and IT security. Special focus is given to maintaining and improving the Company’s alignment with ISO 27001. Additionally, the Company has a cybersecurity incident response plan in place that provides a documented framework for handling high and low severity security incidents and facilitates coordination across multiple parts of the business. The Company has engaged an external consultant to provide oversight and technical expertise to the Company’s ISMS process. Finally, cybersecurity is integrated into the Company’s training as all employees are required to take security awareness training.

Disclosure of the Board’s Responsibility

While management is primarily responsible for assessing and managing cybersecurity risks on a day-to-day basis, the Company’s Board of Directors oversees management’s efforts to assess and manage risk. The Board (in conjunction particularly with

Stockholder and Interested Party Communications with Directors

Stockholders may communicate with the Board of Directors, members of particular committees, or individual directors by sending a letter to such persons in care of the Company’s Chief Executive Officer at its principal executive offices. The Chief Executive Officer has the authority to disregard any inappropriate communications or to take other appropriate actions with respect to any inappropriate communications. If deemed an appropriate communication, the Chief Executive Officer will submit the correspondence to the Chairman of the Board or to the committee or specific director to whom the correspondence is directed. All such communications must be accompanied by a statement of the type and amount of the Company’s securities that the person holds; any special interest, meaning an interest that is not derived from the proponent’s capacity as a stockholder, of the person in the subject matter of the communication; and the address, telephone number and e-mail address, if any, of the person submitting the communication.

Vote Required

Directors are elected by a plurality of votes cast at the Annual Meeting, which means that the seven director nominees receiving the highest number of “FOR” votes will be elected as directors of the Company. Abstentions and broker non-votes are not counted as votes cast with respect to each director and will have no direct effect on the outcome of the election of directors.

Vote Required

Ratification of the appointment of Grant Thornton LLP requires a number of “FOR” votes that is a majority of the voting power of the shares of Common Stock of the Company that are present in person or represented by proxy at the Annual Meeting and entitled to vote on thethis Proposal No. 2, with abstentions countinghaving the same effect as votes against the Proposal.this Proposal No. 2.

The Board of Directors recommends a vote “FOR” the ratification of the appointment of Grant Thornton LLP.

Donna Shiromahas served as General Counsel, Chief Compliance Officer, and Corporate Secretary since June 2018. Ms. Shiroma has more than 20 years of legal and compliance experience in thepharmaceutical and medical device industries and has played an instrumental role in transitioning companies from clinical to commercial entities. Prior to joining the Company, she served in roles of increasing responsibility as corporate counsel, general counsel, vice president of legal, chief privacy andofficer, chief compliance officer, and chief commercial officer forand general counsel. Her prior professional experiences are with: Astex Pharmaceuticals from 2017 to 2018, Ascend Therapeutics from 2008 to 2017, PDL BioPharma from 2006 to 2008, and several Johnson & Johnson companies.companies from 2001 to 2006. Ms. Shiroma holds a B.S. in Environmental Sciences from University of California, Berkeley, and a Juris Doctor degree from Santa Clara University School of Law. She is licensed in the State of California as an attorney.